CG Oncology Initiated at Peer Perform by Wolfe Research

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology initiated with a Peer Perform at Wolfe Research

CG Oncology's Creto Combination Could Drive Better Efficacy in BCG-Exposed NMIBC, UBS Says

Wedbush Remains a Buy on CG Oncology, Inc. (CGON)

CG Oncology Price Target Maintained With a $100.00/Share by HC Wainwright & Co.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), ProKidney (PROK) and CG Oncology, Inc. (CGON)

CG Oncology, Inc. (CGON) Receives a Rating Update from a Top Analyst

CG Oncology reports first results from CORE-008 Cohort CX

CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer

CG Oncology reports Phase 2 CORE-008 combo trial posts 92.3% complete response rate

CG Oncology Inc - No Grade 3 or Higher Treatment-Related Adverse Events or Deaths Reported

CG Oncology Inc - High-Grade Event-Free Survival 96.0% at 3 Months, 89.5% at 6 Months in ITT Population

CG Oncology Inc - Efficacy Comparable Across Treatment Arms and Bcg-Exposed or Bcg-Unresponsive Populations

CG Oncology Reports Positive First Results From Core‑008 Cohort Cx Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk Bcg-Exposed and Bcg-Unresponsive Patients

CG Oncology Price Target Raised to $82.00/Share From $77.00 by Truist Securities

CG Oncology, Inc. (CGON) Gets a Buy from Truist Financial

CG Oncology Inc : Truist Securities Raises Target Price to $82 From $77

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

CG Oncology to present Phase 2 trial results for cretostimogene-gemcitabine combo in NMIBC